Alteogen Inc
KOSDAQ:196170
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
67 800
445 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alteogen Inc
Alteogen Inc
Total Equity
Alteogen Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Equity
₩177.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Equity
₩17T
|
CAGR 3-Years
67%
|
CAGR 5-Years
45%
|
CAGR 10-Years
31%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Equity
₩1.7T
|
CAGR 3-Years
86%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Total Equity
₩1.3T
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Equity
₩817.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Equity
₩480.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
Glance View
Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.
See Also
What is Alteogen Inc's Total Equity?
Total Equity
177.3B
KRW
Based on the financial report for Sep 30, 2024, Alteogen Inc's Total Equity amounts to 177.3B KRW.
What is Alteogen Inc's Total Equity growth rate?
Total Equity CAGR 5Y
23%
Over the last year, the Total Equity growth was 10%. The average annual Total Equity growth rates for Alteogen Inc have been 1% over the past three years , 23% over the past five years .
You don't have any saved screeners yet
